039200.KQ Oscotec Inc.
KOEHealthcareAs of 2026-08-09 03:23
Why 039200.KQ matters now
Oscotec Inc. (039200.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩34,950.00 with -1.13% on the session and ₩1.34T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 23.98, gross margin 97.6%, and operating margin 49.6%.
Valuation
P/E (TTM)
23.98
PEG
—
P/B
7.47
P/S
13.17
EV/EBITDA
21.17
DCF Value
—
FCF Yield
2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.6%
Operating Margin
49.6%
Net Margin
54.9%
ROE
37.2%
ROA
25.1%
ROIC
24.8%
Listing Info
Market
Korea
Exchange
KOE
Currency
KRW
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
KR
Oscotec Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutic drugs. Its primary focus lies in advancing a pipeline of investigational medicines, including a SYK inhibitor currently in Phase IIa clinical trials for the treatment of both rheumatoid arthritis and immune thrombocytopenia. Another key asset is an FLT3 inhibitor, undergoing Phase I clinical evaluation for acute myeloid leukemia. The company is also developing an EGFR double mutation inhibitor aimed at non-small cell lung cancer, and an Anti-Tau antibody in the preclinical stage for Alzheimer's disease. Beyond its pharmaceutical endeavors, Oscotec Inc. diversifies its offerings with a range of dental health products, such as bone graft materials like InduCera, BioCera-F, and SynCeraII, alongside membranes including LysoGide and CollaGuide. Additionally, it markets functional ingredients designed to address specific health concerns, such as OPB for osteoporosis, AIF for arthritis, SGA for enhancing bone growth, and PRF-K for periodontal conditions. Established in 1988, the company, originally known as Oscotec Co., Ltd, adopted its current name, Oscotec Inc., in June 1999. It is headquartered in Seongnam, South Korea.